



## **Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022**

June 8, 2022

FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis (NASH), obesity and cancer, today announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis (NASH) programs within the Company's portfolio were accepted for presentation at The International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom. The [abstracts](#) were published in the July supplement of the Journal of Hepatology.

Details of the Terns presentations at The International Liver Congress 2022 are as follows:

### **Oral Presentation**

**Title:** Multiple doses of thyroid hormone receptor-beta agonist TERN-501 were well-tolerated and resulted in significant dose-dependent changes in serum lipids and sex hormone binding globulin in a first-in-human clinical study

**Publication Number:** OS123

**Presenter:** Cara Nelson

**Date and Time:** Saturday, June 25 6:15 p.m. BT

### **Poster Presentations**

**Title:** Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study

**Publication Number:** SAT107

**Presenter:** Kris Kowdley

**Title:** Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients

**Publication Number:** SAT108

**Presenter:** Cara Nelson

**Title:** TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study

**Publication Number:** SAT106

**Presenter:** Kris Kowdley

**Title:** Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study

**Publication Number:** SAT142

**Presenter:** Mazen Nouredin

### **About Terns Pharmaceuticals**

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as NASH, obesity and cancer. Terns' pipeline includes four clinical stage development programs including a THR-β agonist, an allosteric BCR-ABL inhibitor, an FXR agonist, a VAP-1 inhibitor, and a preclinical small-molecule GLP-1 receptor agonist program. For more information, please visit: [www.ternspharma.com](http://www.ternspharma.com).

### **Contacts for Terns**

#### **Investors**

Justin Ng

[investors@ternspharma.com](mailto:investors@ternspharma.com)

#### **Media**

Jenna Urban

Berry & Company Public Relations

[media@ternspharma.com](mailto:media@ternspharma.com)